Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus
| Autor: | Marilyn K. Boardman, Linong Ji, Pankaj Agarwal, Harry Haber, Kelly Guerrettaz, Chien-Wen Chou, Yukiko Onishi, Chul Woo Ahn |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
Nausea Endocrinology Diabetes and Metabolism Population Type 2 diabetes Hypoglycemia Weight loss Internal medicine Diabetes mellitus Internal Medicine medicine education education.field_of_study Asian business.industry Articles General Medicine medicine.disease Clinical Science and Care Tolerability Exenatide Original Article medicine.symptom business medicine.drug |
| Zdroj: | Journal of Diabetes Investigation |
| ISSN: | 2040-1116 |
| DOI: | 10.1111/j.2040-1124.2012.00238.x |
| Popis: | Aims/Introduction To compare safety and efficacy of the extended-release formulation exenatide once weekly (EQW) vs exenatide twice daily (EBID) for 26 weeks in type 2 diabetes patients from China, India, Japan, South Korea and Taiwan. Materials and Methods A randomized, comparator-controlled, open-label study included 681 patients with type 2 diabetes inadequately controlled (hemoglobin A1c [HbA1c] ≥7 and ≤11%) with oral antihyperglycemic medications (OAMs). Patients added 2 mg EQW or 10 μg EBID to current OAMs. Safety was re-evaluated 10 weeks after last treatment. Results EQW was superior to EBID on HbA1c measures at week 26 (Least-squares mean treatment difference: −0.31% [95% confidence interval −0.49, −0.14%]). More EQW-treated patients achieved target HbA1c ≤7.0% (P = 0.003), ≤6.5% (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text